Altered Rous sarcoma virus gag polyprotein processing and its effects on particle formation

Journal of Virology

Volumn 71, Issue 3, 1997, Pages 2083-2091

  Xiang, Yan ^a   Ridky, Todd W ^a   Krishna, Neel K ^b   Leis, Jonathan ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GAG PROTEIN; SERINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CONTROLLED STUDY; COVALENT BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; ROUS SARCOMA ONCOVIRUS; VIRUS PARTICLE;

EID: 0031054525     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.3.2083-2091.1997     Document Type: Article

References (38)

1. Aiyar, A., Y. Xiang, and J. Leis. 1995. Site-directed mutagenesis using overlap extension PCR. Methods Mol. Biol. 57:177-191.
2. Bennett, R. P., T. D. Nelle, and J. W. Wills. 1993. Functional chimeras of Rous sarcoma virus and human immunodeficiency virus Gag proteins. J. Virol. 67:6487-6498.
3. Bizub, D., I. T. Weber, C. E. Cameron, J. P. Leis, and A. M. Skalka. 1991. A range of catalytic efficiencies with avian retroviral protease subunits genetically linked to form single polypeptide chains. J. Biol. Chem. 266:4951-4958.
4. Bryant, M., and L. Ratner. 1990. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA 87:523-527.
5. Burstein, H., D. Bizub, and A. M. Skalka. 1991. Assembly and processing of avian retroviral Gag polyproteins containing linked protease dimers. J. Virol. 65:6165-6172.
6. Burstein, H., D. Bizub, M. Kotler, G. Schatz, V. M. Vogt, and A. M. Skalka. 1992. Processing of avian retroviral Gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J. Virol. 66:1781-1785.
7. Cameron, C., B. Grinde, P. Jacques, J. Jentoft, J. Leis, A. Wlodawer, and I. Weber. 1993. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. J. Biol. Chem. 268:11711-11720.
8. Cameron, C. E., B. Grinde, J. Jentoft, and J. Leis. 1992. Mechanism of inhibition of retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between Gag p2 and p10 proteins. J. Biol. Chem. 267:23735-23741.
9. Cameron, C. E., T. W. Ridky, S. Shulenin, J. Leis, I. T. Weber, T. Copeland, A. Wlodawer, H. Burstein, D. Bizub-Bender, and A. M. Skalka. 1994. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J. Biol. Chem. 269:11170-11177.
10. Campbell, S., and V. M. Vogt. 1995. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J. Virol. 69:6487-6497.
11. Crawford, S., and S. P. Goff. 1985. A deletion mutation in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J. Virol. 53:899-907.
12. Debouck, C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 8:153-164.
13. Doyon, L., G. Croteau, D. Thibeault, F. Polin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
14. Erikson, E., J. Brugge, and R. Erikson. 1977. Phosphorylated and nonphosphorylated forms of avian sarcoma virus polypeptide p19. Virology 80:177-185.
15. Gelderblom, H. 1990. Morphogenesis, maturation, and fine structure of lentiviruses, p. 159-180. In L. H. Pearl (ed.), Retroviral proteases: control of maturation and morphogenesis. Stockton Press, New York, N.Y.
16. Grinde, B., C. Cameron, J. Leis, I. Weber, A. Wlodawer, H. Burstein, D. Bizub, and A. M. Skalka. 1992. Mutations that alter the activity of the Rous sarcoma virus protease. J. Biol. Chem. 267:9481-9490.
17. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
18. Katz, R. A., and A. M. Skalka. 1994. The retroviral enzymes. Annu. Rev. Biochem. 63:133-173.
19. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
20. Krausslich, H. G. 1991. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc. Natl. Acad. Sci. USA 88:3213-3217.
21. ++/phospholipid-dependent protein kinase. Eur. J. Biochem. 179:415-422.
22. Pepinsky, R., J. A. Papayannopoulos, E. P. Chow, N. K. Krishna, R. C. Craven, and V. M. Vogt. 1995. Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses. J. Virol. 69:6430-6438.
23. Ridky, T., and J. Leis. 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270:29621-29623.
24. Ridky, T. W., D. Bizub-Bender, C. E. Cameron, I. T. Weber, A. Wlodawer, T. Copeland, A. M. Skalka, and J. Leis. 1996. Programming the Rous sarcoma virus protease to cleave new substrate sequences. J. Biol. Chem. 271:10538-10544.
25. Sellos-Moura, M., and V. M. Vogt. 1996. Proteolytic activity of purified avian sarcoma and leukemia virus NC-PR protein expressed in Escherichia coli. Virology 221:335-345.
26. Stewart, L., G. Schatz, and V. M. Vogt. 1990. Properties of avian retrovirus particles defective in viral protease. J. Virol. 64:5076-5092.
27. Weber, I. T. 1990. Comparison of the crystal structures and inter subunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J. Biol. Chem. 265:10492-10496.
28. Weldon, R. A., Jr., and J. W. Wills. 1993. Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J. Virol. 67:5550-5561.
29. Wills, J. W. Personal communication.
30. Wills, J. W., R. C. Craven, and J. A. Achacoso. 1989. Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J. Virol. 63:4331-4343.
31. Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral gag proteins. AIDS 5:639-654.
32. src. J. Virol. 65:3804-3812.
33. Wills, J. W., C. E. Cameron, C. B. Wilson, Y. Xiang, R. P. Bennett, and J. Leis. 1994. An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J. Virol. 68:6605-6618.
34. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-585.
35. gag late assembly domain. J. Virol. 70:5695-5700.
36. Zhang, Z. Y., R. A. Poorman, L. L. Maggiora, R. L. Heinrikson, and F. J. Kezdy. 1991. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 266:15591-15594.
37. Zybarth, G., H. G. Krausslich, K. Partin, and C. Carter. 1994. Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain. J. Virol. 68:240-250.
38. Zybarth, G., and C. Carter. 1995. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR auto processing. J. Virol. 69:3878-3884.